B-cell Lymphoma Research 

Lixin Rui, PhD, is a National Institutes of Health-funded investigator in basic and translational lymphoma research.

His research uses multi-omics approaches and animal models to identify potential molecular targets in cell signaling pathways for development of new therapeutic strategies.

Portrait of Dr. Lixin Rui

Discovering Molecular Targets in B-cell Receptor Pathways

The major research focus of Dr. Rui’s laboratory is the molecular mechanisms of B-cell receptor and JAK-STAT signaling pathways and epigenetic enzymes, including protein arginine methyltransferase 5 (PRMT5) and DNA methyltransferases (DNMTs), in lymphomagenesis.

His research team employs a multidisciplinary approach, using biochemistry, RNA interference, genomic technologies (e.g., ChIP-seq, RNA-seq and single-cell RNA-seq), CRISPR/Cas9 and systems biology methods, to identify mechanisms downstream of the B-cell receptor and JAK-STAT signaling pathways and establish the function of these epigenetic enzymes in B cell lymphoma.

The goal of his research is to discover molecular targets in these pathways for therapeutic, diagnostic and prognostic development of B-cell lymphoma.

Research Team

Postdoctoral Research Assistant

Graduate Research Assistant

Graduate Research Assistant

Graduate Research Assistant

Samantha Babel

Samantha Bebel

Undergraduate Student

Madelyn Chen

Madelyn Chen

Undergraduate Student

Ruoyu Chen

Ruoyu Chen

Undergraduate Student

Paul Selberg

Paul Selberg

Undergraduate Student

photo of Dr. Lixin Rui's hand pointing at heatmap charts on a computer screen
Join Us!

There are opportunities for motivated individuals in the Rui Lab! We are currently seeking undergraduates, graduate students and postdocs interested in cell signaling and cancer genomic/epigenetic research in B-cell lymphoma.

If you are interested in joining the group, please send your CV and a brief description of your research experience and interests to Dr. Rui.

Active Projects

  • EGR1-mediated drug resistance in diffuse large B cell lymphoma
  • Role of DNMT3A and DNMT3B in mantle cell lymphoma 
  • PRMT5 in activation of the PI3K signaling pathway

Funding Support

Dr. Rui’s research is funded by the National Institutes of Health/National Cancer Institute.

closeup of a male scientist in white lab coat working in the lab

Help Us Transform Medicine

You can help support research by making a gift to the Department of Medicine's Excellence in Hematology/Oncology Fund.